{"id":278358,"date":"2021-06-18T21:02:22","date_gmt":"2021-06-18T18:02:22","guid":{"rendered":"https:\/\/en.buradabiliyorum.com\/thiel-backed-psychedelic-drugmaker-valued-at-3-2b-in-nasdaq-debut\/"},"modified":"2021-06-18T21:02:22","modified_gmt":"2021-06-18T18:02:22","slug":"thiel-backed-psychedelic-drugmaker-valued-at-3-2b-in-nasdaq-debut","status":"publish","type":"post","link":"https:\/\/buradabiliyorum.com\/en\/thiel-backed-psychedelic-drugmaker-valued-at-3-2b-in-nasdaq-debut\/","title":{"rendered":"#Thiel-backed psychedelic drugmaker valued at $3.2B in Nasdaq debut"},"content":{"rendered":"

“#Thiel-backed psychedelic drugmaker valued at $3.2B in Nasdaq debut<\/strong>”<\/p>\n

\n

Shares of\u00a0Atai\u00a0Life Science<\/a>s, backed by billionaire investor Peter Thiel, surged 40 percent in their U.S. stock market debut on Friday, giving the German psychedelics startup a market capitalization of $3.19 billion.<\/p>\n

The Berlin-based biotech startup, which is exploring the use of psychedelic treatments for mental illnesses, raised $225 million from selling 15 million shares in its upsized initial public offering on Thursday.<\/p>\n

The company\u2019s shares opened at $21, higher than the IPO price of $15, but gave up early gains to trade flat by 1600 GMT.<\/p>\n

Atai\u00a0was co-founded in 2018 by German investor Christian Angermayer, an advocate of the benefits of using psychedelics such as psilocybin to treat depression, anxiety and substance use disorders. The German startup has backed several companies developing such therapies.<\/p>\n

Psilocybin, the psychedelic active compound in magic mushrooms, was found to be at least as effective as escitalopram, a leading antidepressant drug, in a study by British scientists.<\/p>\n

\n
\"Purple
Atai founder Christian Angermayer is an advocate of using psychedelics such as psilocybin, found in so-called magic mushrooms like these, to treat mental illness.<\/figcaption>
Getty Images<\/span><\/figcaption><\/figure>\n<\/div>\n

Atai\u00a0was considering floating its shares in the United States in May, Reuters reported in March, citing a source close to the matter.<\/p>\n

Its debut comes at a time when U.S. IPOs have already raised $171 billion in the first six months of the year, scorching past the 2020 record of $168 billion, according to data from Dealogic.<\/p>\n

Angermayer has backed about 30 biotech companies, including immunotherapies firm Sensei Biotherapeutics, mental healthcare company Compass Pathways and artificial intelligence-powered drug discovery platform AbCellera Biologics , all of which listed in the United States in recent months.<\/p>\n

\n
\"A
Christian Angermayer (seen here at a 2010 tech conference) in 2018 founded Atai, which has the backing of billionaire investor Peter Thiel.<\/figcaption>
Getty Images for Hubert Burda Media<\/a><\/span><\/figcaption><\/figure>\n<\/div>\n

Germany-based laser communication technologies firm Mynaric and data center operator Northern Data, both partially owned by Angermayer, are also planning to list on the Nasdaq later in 2021 or in 2022, Reuters reported on Thursday.<\/p>\n

Credit Suisse, Citigroup, Cowen and Berenberg were the lead underwriters for the offering.\n <\/p><\/div>\n

If you liked the article, do not forget to share it with your friends. Follow us on\u00a0Google News<\/a><\/span>\u00a0too, click on the star and choose us from your favorites.<\/span><\/strong><\/p><\/blockquote>\n

\n

For forums sites go to Forum.BuradaBiliyorum.Com<\/a><\/span><\/strong><\/p>\n<\/blockquote>\n

\n

If you want to read more News<\/a> articles, you can visit our News category.<\/a><\/span><\/strong><\/p>\n<\/blockquote>\n

Source<\/a><\/span><\/p>\n","protected":false},"excerpt":{"rendered":"

“#Thiel-backed psychedelic drugmaker valued at $3.2B in Nasdaq debut” Shares of\u00a0Atai\u00a0Life Sciences, backed by billionaire investor Peter Thiel, surged 40 percent in their U.S. stock market debut on Friday, giving the German psychedelics startup a market capitalization of $3.19 billion. The Berlin-based biotech startup, which is exploring the use of psychedelic treatments for mental illnesses,…<\/p>\n","protected":false},"author":1,"featured_media":278359,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"fifu_image_url":"https:\/\/nypost.com\/wp-content\/uploads\/sites\/2\/2021\/06\/thiel-backed-atai-3bvalue.jpg?quality=90&strip=all&w=1200","fifu_image_alt":"","footnotes":""},"categories":[70897],"tags":[109769,74572,5007,73799],"class_list":["post-278358","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-6-18-21","tag-biotech","tag-ipo","tag-peter-thiel"],"_links":{"self":[{"href":"https:\/\/buradabiliyorum.com\/en\/wp-json\/wp\/v2\/posts\/278358","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/buradabiliyorum.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/buradabiliyorum.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/buradabiliyorum.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/buradabiliyorum.com\/en\/wp-json\/wp\/v2\/comments?post=278358"}],"version-history":[{"count":0,"href":"https:\/\/buradabiliyorum.com\/en\/wp-json\/wp\/v2\/posts\/278358\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/buradabiliyorum.com\/en\/wp-json\/wp\/v2\/media\/278359"}],"wp:attachment":[{"href":"https:\/\/buradabiliyorum.com\/en\/wp-json\/wp\/v2\/media?parent=278358"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/buradabiliyorum.com\/en\/wp-json\/wp\/v2\/categories?post=278358"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/buradabiliyorum.com\/en\/wp-json\/wp\/v2\/tags?post=278358"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}